Brn-2/BRN2/POU3F2 CRISPR Activation Plasmid (h): sc-400392-ACT

POU3F2 (BRN2/Brn-2) is a POU-homeodomain transcription factor that binds octamer motifs to control gene programs governing neural lineage commitment, neuronal differentiation, and maintenance of cell identity. In the developing and adult nervous system, BRN2 coordinates transcriptional networks with other neurogenic regulators to modulate chromatin state and promote context-specific expression of neuronal markers. Dysregulated POU3F2 activity has been linked to altered differentiation states and lineage plasticity in cancer and neurodevelopmental phenotypes, making it a useful node for studying transcriptional control of cell fate. Its downstream effects intersect with pathways involved in stemness, migration, and stress-adaptive transcriptional rewiring.

Brn-2/BRN2/POU3F2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous POU3F2 expression without altering the underlying DNA sequence.

Brn-2/BRN2/POU3F2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the POU3F2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the POU3F2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Brn-2/BRN2/POU3F2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native POU3F2 locus and enabling the study of Brn-2/BRN2/POU3F2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Brn-2/BRN2/POU3F2 pathway restoration in tumor cells with silenced or reduced POU3F2 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.